|Stage of funding:||Current|
ReVision Optics®, Inc., (RVO) is a privately held corporation headquartered in Southern California, USA.
ReVision Optics focuses on the research and development of innovative optical solutions dedicated to presbyopic vision correction. ReVision’s Raindrop™ Near Vision Inlay offers a unique, patented refractive surgery solution. The inlay is designed to improve the near vision that has been lost by the eye’s natural aging process called presbyopia. This is a new technology in refractive eye surgery whereby a corneal inlay made of a hydrogel is implanted just beneath the surface of the eye. The Raindrop inlay provides an ideally suited surgical option for near and intermediate vision enhancement.
ReVision’s approach harnesses cutting edge technology. The outpatient procedure is completed in a few minutes and near eyesight is quickly recovered within the first several days. The inlay is invisible, easily implanted, minimally invasive and the surgery is reversible.
Revision’s Raindrop is currently in a prospective, multicenter U.S. FDA regulated Phase III clinical trial that is evaluating the safety and effectiveness of the device. Clinical results thus far indicate a significant improvement in near and intermediate vision after the surgery and persistence of results for a long period of time.
Funds raised in this round of investment will be used to complete the U.S. FDA trial, expand ReVision’s commercial efforts outside the US and to undertake clinical trials in Russia, leading to registration and commercialization of the product.
The Raindrop™ Near Vision Inlay is a lens made up of nearly 80% water. It’s like a drop of water, completely clear and so small, no one will ever know you have it – not even you!
Raindrop gently changes the curvature of your eye, allowing you to see clearly when looking at objects up close as well as at intermediate and far distances.
Its placement allows light to focus correctly on the retina, dramatically improving your near vision.
NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 2a study evaluating NDV-3A for the reduction of Staphylococcus aureus (S. aureus) colonization in a high-risk population of military trainees. The study is being conducted with the Uniformed Services University of the Health Sciences (USU) and is enrolling U.S. Army Infantry trainees at Fort Benning, GA. NDV-3A is the company’s lead development candidate to potentially treat antimicrobial resistant fungal and bacterial pathogens.
12 April 2018
30 March 2018
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
14 March 2018